Why Invest in Med-X Before the Planned Nasdaq Listing?

Why Invest in Med-X Before the Planned Nasdaq Listing? Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX) – and for investors, the biggest potential upside comes before the bell rings. The greatest wealth creation happens in the gap between the private and public markets. At the private stage, you buy at a fixed valuation based on fundamentals. Once public, the market prices in future growth. That's where early investors often see the most potential dramatic appreciation. Med-X's Setup: Nasdaq ticker MXRX reserved Listing qualifications nearly complete Sponsored by Maxim Group Investment Bank Zero debt, established revenue base NASDAQ Ticker: MXRX Reserved! Invest Now at $4 Per Share The Real Opportunity to Become a Shareholder Is Now! Med-X is a botanical pesticide company replacing chemical toxins with proven, plant-based solutions. With $6.4M in sales, no long-term debt, and expanding into 41 markets, the company is positioned to capture the surge in global demand for safer pest control. As the world shifts to sustainable solutions, early investors could benefit from the same type of market recognition that transformed sectors led by innovators like Tesla and Zoom – only this time, in clean pest control. Simpler. Safer. More Effective Pesticides. Become a Med-X shareholder at $4 per share before the Nasdaq plans unfold... Disclosures This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com

 

 

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all responsibility and liability arising from the subsequent use of your email address that is made possible by your submission of your email address above. You are receiving this email from Zacks Investment Research because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof. Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here to unsubscribe. Zacks Investment Research 101 N Wacker Drive, Suite 1500 Chicago, IL 60606